Generics History Hobbles Trial Work In China
This article was originally published in PharmAsia News
NEW YORK - Fast, unpredictable change in fragmented China - where companies face retention and regulatory challenges despite in many cases being revenue-generating - brings risk as well as possibility
You may also be interested in...
AstraZeneca’s Head Of R&D Asia Patrick Keohane On Balancing East And West: An Interview With PharmAsia News (Part 1 of 2)
AstraZeneca's Head of R&D in Asia Patrick Keohane sat down with PharmAsia News' Australia bureau to talk about AstraZeneca's footprint in Asia and how the company's thinking is changing as a result of looking toward Asia.
SHANGHAI - The pharmaceutical industry should lobby the Chinese government to relax requirements for IND approvals that discourage multinational companies from sponsoring clinical trials in China, according to Hutchison MediPharma Managing Director Samantha Du
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).